

July 24, 2015



# **EyeGate Pharma Receives USPTO Notice of Allowance for Proprietary Dexamethasone Phosphate Formulation**

## **Patent to Provide Broad Coverage for Steroid Delivered Via Ocular Iontophoresis**

WALTHAM, Mass., July 24, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its lead product candidate, EGP-437. The patent covers a method of treating eye conditions using EyeGate's proprietary Dexamethasone Phosphate pharmaceutical formulation delivered by ocular iontophoresis. The patent is not limited to any particular eye condition or to a particular iontophoretic device or method, but rather is directed at the delivery of this formulation through iontophoresis to the eye of patients in need of treatment .

"This is an important addition to our patent portfolio and critical for the protection our proprietary technology as we continue rigorous and controlled testing of iontophoretic Dexamethasone Phosphate to understand its potential in our initial target indications of macular edema and non-infectious anterior uveitis," said Stephen From, President and Chief Executive Officer of EyeGate Pharma. "By protecting the method of delivering this formulation through iontophoresis, we have substantially more control over this unique and potentially paradigm-shifting therapeutic option. We look forward to continuing the evaluation of EGP-437 in macular edema and uveitis, and to further development initiatives aimed at bringing novel, injection-sparing treatments to patients in need."

EGP-437, EyeGate Pharma's first product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through our proprietary innovative drug delivery system, the EyeGate® II Delivery System. EGP-437 is being evaluated for treatment of non-infectious anterior uveitis and macular edema. Iontophoresis is capable of delivering substantially higher ocular drug concentrations leading to greater bioavailability and therapeutic effect, and reducing the frequency of dosing. The EyeGate® II Delivery System has the potential to offer a non-invasive method of drug delivery as an alternative to the current delivery modalities used for treating ocular diseases, such as eye drops and ocular injections.

### **About EyeGate:**

EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the

eye. EGP-437, the Company's first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate's proprietary innovative drug delivery system, the EyeGate(R) II Delivery System. For more information, please visit [www.EyeGatePharma.com](http://www.EyeGatePharma.com).

**Safe Harbor Statement:**

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate's products, including EGP-437, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading "Risk Factors" contained in our Annual Report on Form 10-K filed with the SEC on March 31, 2015, or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

CONTACT: Lee Roth / Joseph Green  
The Ruth Group for Eyegate Pharmaceuticals  
646-536-7012 / 7013  
[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com) / [jgreen@theruthgroup.com](mailto:jgreen@theruthgroup.com)

Source: Eyegate Pharmaceuticals, Inc.